Medios AG (MEDOF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Medios AG (MEDOF) trades at $50.00 with AI Score 45/100 (Grade C). Medios AG is a German wholesale supplier of specialized pharmaceutical products, operating through Pharmaceutical Supply and Patient-Specific Therapies divisions. Market cap: $1.28B, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for MEDOF: MEDOF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates MEDOF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
MEDOF: the 1 perspectives are evenly split.
How is this calculated? →Medios AG (MEDOF) Healthcare & Pipeline Overview
Medios AG is a German wholesale distributor specializing in critical care pharmaceuticals and patient-specific therapies. The company supplies pharmacies with medications for oncology, neurological disorders, and autoimmune diseases, alongside customized therapeutic solutions, positioning itself in the evolving specialized medicine market.
What Is the Investment Thesis for MEDOF?
Medios AG operates within the specialized pharmaceutical and personalized medicine sectors in Germany, presenting a unique investment profile. The company's dual focus on wholesale supply for critical conditions and patient-specific therapies positions it to capitalize on the growing demand for highly specialized and individualized medical treatments. Key value drivers include its established distribution network across Germany and its expertise in pharmaceutical compounding, which addresses unmet needs in the healthcare landscape. The market capitalization stands at $1.28 billion, with a P/E ratio of 21.2, reflecting investor confidence in its future earnings potential. While the profit margin is 0.7% and gross margin is 6.9%, typical for wholesale distribution, the company's strategic niche in high-value specialized products offers potential for margin expansion through efficiency and increased demand for bespoke solutions. Growth catalysts are primarily driven by the ongoing shift towards personalized medicine and the increasing prevalence of complex diseases requiring specialized pharmacological interventions. However, the company faces inherent risks, including potential regulatory changes within the German pharmaceutical market and persistent pricing pressures, which are common across the industry. Its Beta of 1.31 suggests higher volatility relative to the broader market, a factor for investors to consider.
Based on FMP financials and quantitative analysis
MEDOF Key Highlights
- Market Capitalization: $1.28 billion, reflecting its scale within the German specialized pharmaceutical distribution sector.
- P/E Ratio: 21.17, indicating investor expectations relative to its earnings.
- Gross Margin: 6.9%, demonstrating the profitability of its wholesale and patient-specific therapy operations.
- Profit Margin: 0.7%, highlighting the net profitability after all expenses.
- Beta: 1.31, suggesting higher volatility compared to the broader market.
Who Are MEDOF's Competitors?
MEDOF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CWB State Street SPDR Bloomberg Convertible Securities ETF | $105.34 | +0.92% | $4.62B | 47 |
| TDV ProShares - S&P Technology Dividend Aristocrats ETF | $100.89 | +1.33% | $293.21M | 47 |
| DAUG FT Vest U.S. Equity Deep Buffer ETF - August | $46.97 | +0.26% | $363.40M | 47 |
| KSTR KraneShares SSE STAR Market 50 Index ETF | $28.75 | +2.00% | $67.07M | 47 |
| RWMBX American Funds Washington Mutual R2 | $65.59 | +0.74% | $147.31B | 46 |
| VQSRX Virtus KAR Small-Cap Value Fund | $25.02 | +0.68% | $582.06M | 46 |
| EVPF Eaton Vance Preferred Securities and Income ETF | $50.38 | +0.28% | $17.82M | 46 |
| GSSQX Goldman Sachs U.S. Equity Insights Fund | $68.40 | +0.09% | $1.16B | 46 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MEDOF's Key Strengths?
- Specialization in high-demand critical care pharmaceuticals and patient-specific therapies.
- Established wholesale distribution network across Germany.
- Expertise in pharmaceutical compounding for individualized treatments.
- Dual operational model addressing both broad supply and niche personalized medicine needs.
What Are MEDOF's Weaknesses?
- Relatively low profit margin of 0.7% and gross margin of 6.9%.
- Potential reliance on the German market for its primary operations.
- Limited public information on specific operational metrics beyond financial ratios.
- Unknown disclosure status on the OTC market impacting transparency.
What Could Drive MEDOF Stock Higher?
- Growing demand for specialized pharmaceutical products in Germany, particularly for critical conditions.
- Expansion of patient-specific therapy services to meet the increasing trend towards personalized medicine.
- Potential regulatory developments in Germany that could further support or streamline specialized pharmaceutical compounding and distribution.
- Continued strategic focus on high-value therapeutic areas, potentially leading to market share gains.
What Are the Key Risks for MEDOF?
- Regulatory changes in the German pharmaceutical market impacting distribution, pricing, or product approvals.
- Persistent pricing pressures within the specialized pharmaceutical sector affecting profit margins.
- Intense competition from other pharmaceutical distributors and compounding pharmacies in Germany.
- Dependence on a limited geographic market (Germany) for the majority of its operations.
- Operational challenges related to maintaining a complex supply chain for specialized and customized medications.
What Are the Growth Opportunities for MEDOF?
- Expanding Personalized Medicine Market: The global trend towards personalized medicine, where treatments are tailored to individual patient genetic profiles and specific needs, represents a significant growth opportunity for Medios AG. Its Patient-Specific Therapies segment is directly aligned with this trend, offering customized medications and bespoke therapeutic solutions. As medical science advances and diagnostic capabilities improve, the demand for precisely dosed and compounded pharmaceuticals is expected to increase. Medios AG's established expertise and infrastructure in this area provide a competitive advantage, allowing it to capture a larger share of this evolving market segment within Germany, catering to complex patient requirements that standard drug formulations cannot address.
- Growth in Specialty Pharmaceutical Demand: The incidence of complex and chronic diseases, such as various forms of cancer, neurological disorders, and autoimmune conditions, continues to rise. This drives a sustained and growing demand for specialized pharmaceutical products, which are often high-value and require specific handling and distribution expertise. Medios AG's Pharmaceutical Supply segment, which focuses on these critical therapeutic areas, is well-positioned to benefit from this market expansion. Its role as a reliable wholesale supplier ensures consistent access to these essential medications for pharmacies across Germany, solidifying its market presence and fostering long-term relationships with healthcare providers in this high-growth sector.
- Leveraging Digitalization in Pharmaceutical Logistics: The ongoing digitalization of healthcare logistics offers Medios AG opportunities to enhance efficiency, reduce operational costs, and potentially expand its reach. Implementing advanced supply chain management systems, optimizing inventory control through data analytics, and exploring e-commerce platforms for pharmacy orders could streamline operations. While specific initiatives are not detailed in the provided data, the general industry trend suggests that companies leveraging technology for improved distribution, order fulfillment, and tracking gain significant competitive advantages. Such advancements could enable Medios AG to serve its extensive network of pharmacies more effectively, ensuring timely delivery of critical and patient-specific medications across Germany.
- Strategic Partnerships and Market Consolidation: The German pharmaceutical distribution market, like many others, may present opportunities for strategic partnerships, collaborations, or even targeted acquisitions. By partnering with smaller specialized pharmacies, research institutions, or technology providers, Medios AG could expand its service offerings, geographical footprint, or technological capabilities. Consolidation within the industry could also allow Medios AG to acquire complementary businesses, thereby increasing its market share, diversifying its product portfolio, or gaining access to new therapeutic areas. Such strategic moves, while not explicitly mentioned as current plans, are common growth avenues for established players seeking to strengthen their market position and achieve economies of scale in a competitive environment.
- Favorable Regulatory Environment for Compounding: While regulatory changes can pose risks, a stable or even more supportive regulatory environment for pharmaceutical compounding could present a growth opportunity. As personalized medicine gains traction, regulatory bodies may increasingly recognize the necessity and value of patient-specific therapies, potentially streamlining approval processes or providing incentives for companies like Medios AG. A clear and supportive regulatory framework would reduce operational uncertainties and could encourage greater adoption of customized medications by healthcare providers. Medios AG's established compliance and quality control in this specialized area position it well to adapt to and benefit from any such evolving regulatory landscape within Germany, reinforcing its role as a trusted supplier.
What Opportunities Does MEDOF Have?
- Growing demand for personalized medicine and patient-specific therapies.
- Increasing prevalence of complex diseases driving demand for specialized pharmaceuticals.
- Potential for digitalization to enhance supply chain efficiency and reach.
- Strategic partnerships or acquisitions to expand market share or service offerings.
What Threats Does MEDOF Face?
- Ongoing regulatory changes within the German pharmaceutical market.
- Persistent pricing pressures common in the pharmaceutical distribution industry.
- Competition from other pharmaceutical wholesalers and compounding pharmacies.
- Potential for increased market volatility given its Beta of 1.31.
What Are MEDOF's Competitive Advantages?
- Specialization in critical care pharmaceuticals and patient-specific compounding.
- Established wholesale distribution network covering the German market.
- Expertise in handling and supplying medications for complex and rare diseases.
- Ability to provide bespoke therapeutic solutions tailored to individual patient needs.
- Compliance with stringent German pharmaceutical distribution and compounding regulations.
What Does MEDOF Do?
Medios AG, established in 2016 and headquartered in Berlin, Germany, operates as a comprehensive wholesale supplier of specialized pharmaceutical products throughout Germany. The company's business model is distinctly structured into two core divisions: Pharmaceutical Supply and Patient-Specific Therapies. The Pharmaceutical Supply segment is dedicated to distributing essential medications for a range of critical and complex conditions. This includes vital treatments for oncology, neurological disorders, autoimmune diseases, ophthalmological issues, infectious diseases, and hemophilia. By focusing on these high-need therapeutic areas, Medios AG addresses a significant demand within the German healthcare system, ensuring pharmacies have access to crucial specialized drugs that are often difficult to source through general channels. This strategic emphasis allows the company to build deep expertise and strong relationships within specialized medical fields. The Patient-Specific Therapies segment represents Medios AG’s commitment to personalized medicine, a rapidly evolving area of healthcare. This division specializes in the creation of customized medications tailored precisely to the individual needs of patients. These bespoke therapeutic solutions, which often involve the preparation of tablets with precisely tailored dosages, are typically prepared for dispensing by pharmacies. This capability allows Medios AG to cater to unique patient requirements that cannot be met by standard pharmaceutical products, thereby enhancing therapeutic outcomes and supporting the growing trend towards individualized healthcare. The company's integrated approach, combining broad wholesale distribution with highly specialized compounding services, positions it as a key player in the German pharmaceutical supply chain, particularly for complex and personalized treatment regimens. Its strategic focus on specialized pharmaceuticals and the increasing demand for personalized medicine are central to its operational strategy and market relevance, serving as a critical intermediary between manufacturers and patients via pharmacies.
What Products and Services Does MEDOF Offer?
- Operate as a wholesale supplier of specialized pharmaceutical products throughout Germany.
- Distribute medications for critical conditions such as oncology, neurological disorders, and autoimmune diseases.
- Provide patient-specific therapies, creating customized medications for individual patients.
- Offer bespoke therapeutic solutions, including tablets with precisely tailored dosages.
- Prepare customized medications for dispensing by pharmacies.
- Focus on high-need therapeutic areas within the German healthcare system.
How Does MEDOF Make Money?
- Generate revenue from the wholesale distribution of specialized pharmaceuticals to pharmacies.
- Earn income from providing patient-specific compounding services for customized medications.
- Monetize the supply of critical condition medications across various therapeutic areas.
- Derive value from its dual operational model, combining broad distribution with specialized compounding expertise.
What Industry Does MEDOF Operate In?
Medios AG operates within the dynamic German healthcare sector, specifically in the medical distribution industry, with a strong emphasis on specialized pharmaceuticals and patient-specific therapies. The broader industry is characterized by an increasing demand for advanced treatments for complex diseases and a significant trend towards personalized medicine, where treatments are tailored to individual patient needs. Medios AG positions itself as a critical wholesale supplier, bridging the gap between pharmaceutical manufacturers and pharmacies across Germany. The competitive landscape includes other pharmaceutical wholesalers and specialized compounding pharmacies. Medios AG differentiates itself through its dual operational model, combining broad distribution capabilities for critical care medications with highly specialized compounding services. This niche allows it to address specific market segments that require precision and expertise, navigating an environment often influenced by stringent regulatory frameworks and continuous pricing pressures.
Who Are MEDOF's Key Customers?
- Pharmacies across Germany requiring specialized pharmaceutical products.
- Healthcare providers seeking medications for critical conditions.
- Patients indirectly, through pharmacies, for customized therapeutic solutions.
How Medios AG Is Valued
Medios AG carries a market capitalization of $1.28B, placing it in the small-cap category. Relative to its peer group, MEDOF's quantitative score of 45/100 is roughly in line with the peer average of 47/100.
Company Profile
Medios AG operates in the Medical - Distribution industry within the Healthcare sector. It is headquartered in Berlin, DE. The company is led by CEO Thomas Meier. MEDOF has traded publicly since 2021.
ROE 3%Key Financial Metrics
Return on equity for Medios AG stands at 2.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 1.5%, showing how much profit it generates from its asset base. MEDOF trades at a trailing price-to-earnings ratio of 21.17, roughly in line with the Healthcare sector average of ~23x. Its free cash flow yield is 16.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.92 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 4.7%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 6/9Financial Health
Medios AG's Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 4.53 places it in the safe zone, indicating low near-term bankruptcy risk.
FY2026 estForward Outlook
Wall Street analysts project Medios AG revenue of about $2.11B for fiscal 2026, with EPS near $1.38. The estimate reflects 4 contributing analysts.
MEDOF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Specialization in high-demand critical care pharmaceuticals and patient-specific therapies.
- Established wholesale distribution network across Germany.
- Expertise in pharmaceutical compounding for individualized treatments.
- Dual operational model addressing both broad supply and niche personalized medicine needs.
Bear Case
- Relatively low profit margin of 0.7% and gross margin of 6.9%.
- Potential reliance on the German market for its primary operations.
- Limited public information on specific operational metrics beyond financial ratios.
- Unknown disclosure status on the OTC market impacting transparency.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
MEDOF Latest News
-
Is Now The Time To Look At Buying Medios AG (ETR:ILM1)?
Yahoo! Finance: MEDOF News · May 25, 2026
MEDOF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MEDOF.
Price Targets
Wall Street price target analysis for MEDOF.
MEDOF MoonshotScore
What does this score mean?
The MoonshotScore rates MEDOF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Thomas Meier
Chief Executive Officer
Details regarding Thomas Meier's specific career history, educational background, and previous leadership roles prior to his current position at Medios AG are not provided in the available source data. His professional journey leading up to his role in managing Medios AG's operations, including any relevant experience in pharmaceutical distribution, healthcare management, or specialized compounding, remains undisclosed in the provided information.
Track Record: Specific achievements, strategic decisions, or significant company milestones directly attributable to Thomas Meier's leadership at Medios AG are not detailed in the provided source data. While he is responsible for managing the company's 472 employees and overseeing its strategic direction, explicit information regarding his track record in driving growth, navigating market challenges, or implementing key initiatives is not available.
MEDOF OTC Market Information
Medios AG trades on the OTC (Over-The-Counter) market under the "OTC Other" tier. This tier is distinct from major exchanges like the NYSE or NASDAQ, which have stringent listing requirements regarding financial reporting, minimum share prices, and corporate governance. "OTC Other" generally refers to securities that do not meet the criteria for OTCQX or OTCQB, often due to limited public information or financial disclosure. Companies in this tier may not file with the SEC, leading to less transparent financial reporting compared to exchange-listed or even higher-tier OTC companies. Investors typically face higher risks due to this reduced transparency and oversight.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Reduced transparency due to unknown disclosure status and less stringent reporting requirements.
- Lower liquidity, potentially leading to wider bid-ask spreads and difficulty in trading shares.
- Increased price volatility due to thinner trading volumes and fewer market participants.
- Limited access to reliable and timely financial information for comprehensive analysis.
- Higher risk of fraud or manipulation due to less regulatory oversight compared to major exchanges.
- Verify the company's official website for any direct financial reports or investor relations sections.
- Research any available news releases or public statements from the company.
- Examine the company's business operations and market position in Germany.
- Assess the management team's experience and track record, if information becomes available.
- Consult independent financial databases or services that may track OTC securities.
- Understand the specific regulatory environment for pharmaceutical distribution in Germany.
- Evaluate the company's competitive landscape and growth prospects within its niche.
- Established operations as a wholesale supplier of specialized pharmaceuticals in Germany since 2016.
- Clear business model with two distinct divisions: Pharmaceutical Supply and Patient-Specific Therapies.
- Headquartered in Berlin, Germany, indicating a physical presence and operational base.
- Known CEO, Thomas Meier, managing 472 employees, suggesting an active management structure.
- Focus on a specialized and regulated industry (healthcare/pharmaceuticals) in a developed economy.
What Investors Ask About Medios AG (MEDOF) — Healthcare
What does Medios AG do?
Medios AG operates as a wholesale supplier of specialized pharmaceutical products across Germany, established in 2016. The company is structured into two primary divisions: Pharmaceutical Supply and Patient-Specific Therapies. The Pharmaceutical Supply segment focuses on distributing critical medications for severe conditions such as oncology, neurological disorders, and autoimmune diseases to pharmacies. Concurrently, its Patient-Specific Therapies segment specializes in compounding customized medications tailored for individual patients, including precisely dosed tablets, which are prepared for dispensing by pharmacies. This dual approach allows Medios AG to serve both broad critical care needs and the growing demand for highly individualized therapeutic solutions within the German healthcare system.
How does Medios AG position itself in the German specialized pharmaceutical market?
Medios AG strategically positions itself as a crucial intermediary and specialist within the German pharmaceutical market by focusing exclusively on specialized products and patient-specific therapies. Unlike general pharmaceutical distributors, Medios AG targets high-need areas like oncology, neurology, and autoimmune diseases through its Pharmaceutical Supply division, requiring specific expertise and robust supply chain management. Furthermore, its Patient-Specific Therapies segment addresses the increasing demand for personalized medicine, offering bespoke compounded medications. This dual specialization allows Medios AG to carve out a distinct niche, providing value through its ability to handle complex logistics and deliver tailored solutions that are essential for critical patient care across Germany.
What are the primary operational challenges for Medios AG?
Medios AG faces several operational challenges inherent to the specialized pharmaceutical and distribution sectors. A significant challenge includes navigating the complex and evolving regulatory landscape within the German healthcare system, which can impact product approvals, distribution practices, and pricing structures. The company also contends with ongoing pricing pressures, a common characteristic of the pharmaceutical industry, which can affect profit margins. Furthermore, maintaining a highly efficient and compliant supply chain for both specialized and patient-specific medications requires continuous investment and operational rigor. The competitive environment, coupled with the need to adapt to technological advancements and potential shifts in healthcare policies, presents continuous operational considerations for Medios AG.
What are the key factors to evaluate for MEDOF?
Medios AG (MEDOF) holds an AI score of 45/100 (low). P/E: 21.2x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does MEDOF data refresh on this page?
MEDOF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven MEDOF's recent stock price performance?
Medios AG (MEDOF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialization in high-demand critical care pharmaceuticals and patient-specific therapies. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MEDOF overvalued or undervalued right now?
Medios AG (MEDOF) trades at 21.2x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying MEDOF?
Before investing in Medios AG (MEDOF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited specific data for CEO background and track record.
- No FMP PEER TICKERS provided in source data, hence competitors array is empty.
- Specific market size and timeline data for growth opportunities not provided, qualitative descriptions used.
- OTC disclosure status is unknown, limiting detailed analysis of available reports.